Charles River Laboratories International financials
$295.96+0.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 27 | FY24 Dec 28 | FY23 Dec 30 | FY22 Dec 31 | FY21 Dec 25 | FY20 Dec 26 | FY19 Dec 28 | FY18 Dec 29 | FY17 Dec 30 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B |
| Gross profit | $1.32B | $1.33B | $1.50B | $1.46B | $1.33B | $1.07B | $958.3M | $840.1M | $700.9M | $644.0M |
| Gross margin | 33.0% | 32.9% | 36.4% | 36.8% | 37.7% | 36.7% | 36.6% | 37.1% | 37.7% | 38.3% |
| Operating income | $25.2M | $227.3M | $617.3M | $651.0M | $589.9M | $432.7M | $351.2M | $331.4M | $288.3M | $237.6M |
| Net income | -$144.3M | $10.3M | $474.6M | $486.2M | $391.0M | $364.3M | $252.0M | $226.4M | $123.4M | $154.8M |
| Net margin | −3.6% | 0.3% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% |
| Diluted EPS | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 |
| EBITDA | $804.4M | $804.1M | $931.4M | $954.8M | $855.4M | $667.7M | $549.2M | $493.2M | $419.4M | $364.2M |
| Operating cash flow | $737.6M | $734.6M | $683.9M | $619.6M | $760.8M | $547.0M | $480.9M | $437.4M | $339.1M | $325.1M |
| Free cash flow | $518.5M | $501.6M | $365.4M | $294.9M | $532.0M | $380.5M | $340.4M | $297.4M | $256.7M | $269.8M |
| Diluted shares | 49.6M | 51.6M | 51.5M | 51.3M | 51.4M | 50.6M | 49.7M | 49.0M | 48.6M | 48.0M |
Balance sheet
| Period end | Dec 27 | Dec 28 | Dec 30 | Dec 31 | Dec 25 | Dec 26 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $213.8M | $194.6M | $276.8M | $233.9M | $241.2M | $228.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $2.14B | $2.24B | $2.65B | $2.71B | $2.66B | $1.98B |
| Total assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B |
| Total liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B |
| Shareholders' equity | $3.17B | $3.47B | $3.60B | $2.98B | $2.54B | $2.12B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology